Identifying and overcoming solubility challenges continues to be an important issue for pharmaceutical and biotech drug manufacturers. Estimates of 70% of new drugs still suffer from solubility issues. As a result, industry has responded with the development of enabled formulations to counteract this.

In response, we want to share a presentation deck titled “Discovery Pharmaceutics and Preformulation Considerations for Enabled Formulations” from James Ormes at Merck & Co. Dr. Ormes delivered this talk at one of our recent Global Drug Bioavailability Enhancement Summits. This presentation focuses on Discovery Pharmaceutics/Preformulation concepts. These include solubility and supersaturation, solubility measurements and the difference between activity and solubility. It additionally covers crystallization risk assessments: rapid, moderate and slow crystallizers, mobility, glass transition temperature and impact of humidity, as well as opportunities for discovery pharmaceutics and preformulation scientists to reduce risk?

Scroll through the presentation below……